Literature DB >> 23940064

Identification of an important potential confound in CSF AD studies: aliquot volume.

Jamie Toombs, Ross W Paterson, Michael P Lunn, Jenifer M Nicholas, Nick C Fox, Miles D Chapman, Jonathan M Schott, Henrik Zetterberg.   

Abstract

BACKGROUND: Cerebrospinal fluid (CSF) amyloid β1-42 (Aβ1-42), total tau (T-tau) and phosphorylated tau181 (P-tau) are finding increasing utility as biomarkers of Alzheimer's disease (AD). The purpose of this study was to determine whether measured CSF biomarker concentrations were affected by aliquot storage volume and whether addition of detergent-containing buffer mitigates any observed effects.
METHODS: AD and control CSF was distributed into polypropylene tubes in aliquots of different volumes (50-1500 μL). Aβ1-42, T-tau and P-tau were measured with and without addition of Tween 20 (0.05%).
RESULTS: Measured concentrations of Aβ1-42 increased two-fold with aliquot storage volume. A volume increase of 10 µL caused an Aβ1-42 increase of 0.95 pg/mL [95% confidence interval (CI) 0.36-1.50, p=0.02] in controls, and 0.60 pg/mL (CI 0.23-0.98 pg/mL, p=0.003) in AD samples. Following addition of Tween 20, the positive relationship between Aβ1-42 and aliquot volume disappeared. T-tau and P-tau were not significantly affected.
CONCLUSIONS: CSF aliquot storage volume has a significant impact on the measured concentration of Aβ1-42. The introduction of a buffer detergent at the initial aliquoting stage may be an effective solution to this problem.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23940064     DOI: 10.1515/cclm-2013-0293

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  17 in total

1.  Total protein is an effective loading control for cerebrospinal fluid western blots.

Authors:  Mahlon A Collins; Jiyan An; Danielle Peller; Robert Bowser
Journal:  J Neurosci Methods       Date:  2015-05-22       Impact factor: 2.390

2.  Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers.

Authors:  Tessandra Stewart; Min Shi; Aanchal Mehrotra; Patrick Aro; David Soltys; Kathleen F Kerr; Cyrus P Zabetian; Elaine R Peskind; Peggy Taylor; Leslie M Shaw; John Q Trojanowski; Jing Zhang
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 3.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

4.  Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.

Authors:  Shorena Janelidze; Josef Pannee; Alvydas Mikulskis; Ping Chiao; Henrik Zetterberg; Kaj Blennow; Oskar Hansson
Journal:  JAMA Neurol       Date:  2017-12-01       Impact factor: 18.302

5.  Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results.

Authors:  Jonathan Gooblar; Catherine M Roe; Natalie J Selsor; Matthew J Gabel; John C Morris
Journal:  JAMA Neurol       Date:  2015-12       Impact factor: 18.302

Review 6.  A consensus in Korea regarding a protocol to reduce preanalytical sources of variability in the measurement of the cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Sun Ah Park; Ju Hee Kang; Eun Suk Kang; Chang Seok Ki; Jee Hoon Roh; Young Chul Youn; Seong Yoon Kim; Sang Yun Kim
Journal:  J Clin Neurol       Date:  2015-04       Impact factor: 3.077

7.  Chasing the Effects of Pre-Analytical Confounders - A Multicenter Study on CSF-AD Biomarkers.

Authors:  Maria João Leitão; Inês Baldeiras; Sanna-Kaisa Herukka; Maria Pikkarainen; Ville Leinonen; Anja Hviid Simonsen; Armand Perret-Liaudet; Anthony Fourier; Isabelle Quadrio; Pedro Mota Veiga; Catarina Resende de Oliveira
Journal:  Front Neurol       Date:  2015-07-08       Impact factor: 4.003

8.  Amyloid-beta 42 adsorption following serial tube transfer.

Authors:  Jamie Toombs; Ross W Paterson; Jonathan M Schott; Henrik Zetterberg
Journal:  Alzheimers Res Ther       Date:  2014-01-28       Impact factor: 6.982

9.  Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?

Authors:  Ross W Paterson; Jamie Toombs; Miles D Chapman; Jennifer M Nicholas; Amanda J Heslegrave; Catherine F Slattery; Alexander J M Foulkes; Camilla N Clark; Christopher A S Lane; Philip S J Weston; Michael P Lunn; Nick C Fox; Henrik Zetterberg; Jonathan M Schott
Journal:  Alzheimers Dement (Amst)       Date:  2015-07-02

10.  Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes.

Authors:  Hugo Marcel Johan Vanderstichele; Shorena Janelidze; Leentje Demeyer; Els Coart; Erik Stoops; Victor Herbst; Kimberley Mauroo; Britta Brix; Oskar Hansson
Journal:  J Alzheimers Dis       Date:  2016-05-31       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.